Central aortic blood pressure and augmentation index: comparison between Vasotens® and SphygmoCor® technology
Anatoliy N Rogoza,1 Aleksandr A Kuznetsov2
1Cardiology Research Complex, Moscow, Russian Federation; 2Therapy Research Institute, Siberian branch of Russian Academy of Medical Science, Novosibirsk, Russian Federation
Introduction: The aim of this study is the comparison of Vasotens® technology as used in a device with an oscillometric method of blood pressure measurement (BPLab, Petr Telegin Ltd, Nizhny Novgorod, Russian Federation) against the validated tonometric system (SphygmoCor®, AtCor Medical Pty Ltd, West Ryde, Australia).
Methods: The examinations were carried out in two medical centers. Exclusion criteria included atrial fibrillation, severe cardiac anomalies, heart failure, arrhythmia, decompensated diabetes, the presence of an artificial pacemaker, pregnancy, and BMI > 30. Overall, 160 patients and healthy volunteers were examined. Central aortic systolic blood pressure (aSBP) and augmentation index (aAIx) were obtained by means of applanation tonometry and the oscillometric method was compared.
Results: aSBP and aAIx measured using the BPLab device equates significantly with the same parameters measured by SphygmoCor.
Conclusion: This finding allows the recommendation of Vasotens technology, which can be used with the 24-hour BPLab monitoring system for wide clinical use.
Keywords: central aortic blood pressure, augmentation index, validation, Vasotens®, BPLab®
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.